Sapporo Medical Journal

Abstract : Reducing inflammation can be one of the therapeutic targets in in Chronic Kidney Disease (CKD) patients. Many studies have shown that statins have pleiotropic effects as anti-inflammation. In this study we will be seen interaction of HDL-Cholesterol and hs-CRP to prove the role of statins as an anti-inflammatory and dyslipidemia treatment simultaneously. We compared hs-CRP and HDL Cholesterol/hs-CRP ratio levels in CKD patients who took statins and who did not take statins. Forty samples of CKD patients were taken randomly and then grouped based on their consumption of statin: taking statins (20) and not taking statins (20). There were negative correlation between HDL Cholesterol and hs-CRP (R=-0.374; P= 0.017), positive correlation between HDL Cholesterol/hs-CRP ratio and eGFR (R= 0.421; P= 0.007). The median concentration of hs-CRP in the statin group was significantly lower than in non-statin group (1.80 (1.20 – 5.30) vs 3.60 (1.90 – 11.60); P= 0.038), meanwhile there were not significantly different of median of HDL Cholesterol and HDL Cholesterol/hs-CRP Ratio between group. CKD subjects that consumed statin have a lower hs-CRP compared to subject that did not consume statin. But there was no difference of HDL-Cholesterol/hs-CRP ratio between CKD subjects that consume statin compared to did not consume statin but had a good correlation with eGFR. This result mean that HDL-Cholesterol and hs-CRP monitoring very important in CKD patient with statin treatment.